SLC5A2 and heart failure: The benefits we observed of SGLT-2 inhibitors improving HbA1c levels, BMI, and systolic blood pressure and reducing the risks of admission to hospital for heart failure (compared with DPP-4 inhibitors) and ≥40% decline in eGFR (compared with sulfonylureas) are indicative of a causal mechanism that has some biological plausibility.